Via practica 1/2026
Statin intolerance – from definition to treatment in everyday practice
Statin intolerance represents a significant challenge in the management of dyslipidemia, particularly among patients at high cardiovascular risk. It is defined as the inability to sustain a statin dose required for effective lowering of low-density lipoprotein cholesterol, typically due to muscle-related symptoms or elevations in hepatic transaminases. In routine clinical practice, the reported prevalence ranges from 7–29 %, whereas complete intolerance is relatively uncommon (~3–6 %). Mild myalgias are most frequently encountered, while severe complications such as rhabdomyolysis are rare. Diagnosis relies on establishing a temporal association between treatment initiation and symptoms, alongside exclusion of alternative etiologies such as hypothyroidism, vitamin D deficiency, drug – drug interactions, and excessive physical exertion. Causality should be probed through formal dechallenge – rechallenge, and, where appropriate, by switching the statin molecule or modifying the dosing regimen. Particular attention should be paid to the nocebo effect, which may account for a proportion of subjective complaints without a direct pharmacologic basis. Management includes non-pharmacologic measures (weight reduction, dietary optimization, and physical activity) and pharmacologic strategies employing low-dose or intermittent statin therapy in combination with ezetimibe. For persistent intolerance, bempedoic acid and PCSK9 inhibitors are reasonable options. Most patients, despite some degree of intolerance, can tolerate at least a low statin dose with ezetimibe or other adjunctive therapy, allowing achievement of LDL-cholesterol targets. Wider implementation of alternative regimens may be limited by reimbursement constraints within public health insurance systems.
Keywords: dyslipidemia, statin intolerance, management, symptoms assessment
